Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide.
ECC4703 is a potential new treatment for non-alcoholic fatty liver disease.
The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.
Inclusion Criteria:
Exclusion Criteria:
contact@eccogene.com86-21-61053022
Cohort 1 participants will receive ECC4703 and sulfasalazine.
Cohort 2 participants will receive ECC4703 and pitavastatin.
Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects
ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants
FTIH of ECC4703 in Healthy Volunteers
A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin
Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)
A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)